Detalhe da pesquisa
1.
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Lancet Haematol
; 11(2): e136-e146, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190832
2.
Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
Leuk Lymphoma
; 64(11): 1847-1856, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37539698